🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 85 of 151

  1. NKTR-214

    Nektar Therapeutics UK Limited

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 2 small molecule completed

    1 trial

  2. NKTR-214

    Nektar Therapeutics UK Limited

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  3. NKTR-255

    Nektar Therapeutics UK Limited

    Lung Cancer

    phase 2 small molecule active

    1 trial

  4. NKTR-255

    Nektar Therapeutics UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  5. NKTR-262

    Nektar Therapeutics UK Limited

    Melanoma

    phase 2 small molecule terminated

    1 trial

  6. NKTR-358, Placebo

    Nektar Therapeutics UK Limited

    Alopecia Areata

    phase 2 small molecule active

    1 trial

  7. NKTR-358, Sodium Chloride 0.9% solution

    Nektar Therapeutics UK Limited

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  8. NMD670, NMD670, Placebo

    Lacuna Pharma Pty Ltd

    Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  9. NMD670, Placebo

    Lacuna Pharma Pty Ltd

    Charcot-Marie-Tooth Disease Type 1 and Type 2

    phase 2 small molecule active

    1 trial

  10. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prodromal Schizophrenia

    phase 2 small molecule active

    1 trial

  11. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Major Depressive Disorder

    phase 2 small molecule active

    2 trials

  12. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    2 trials

  13. NMDAE plus AIFA

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial

  14. NMRA-335140 80 mg

    Neumora Therapeutics

    Major Depressive Episode Associated With Bipolar II Disorder

    phase 2 small molecule completed

    1 trial

  15. NNC6019-0001

    Novo Nordisk A/S

    Transthyretin Amyloid Cardiomyopathy (ATTR CM)

    phase 2 small molecule completed

    1 trial

  16. NOE-105, Placebo, Hard Capsules

    Lacuna Pharma Pty Ltd

    Tourette Syndrome

    phase 2 small molecule active

    1 trial

  17. NORETHISTERONE AND ETHINYLESTRADIOL , IDE196 (LXS196), IDE196 (LXS196), METFORMIN HYDROCHLORIDE

    IDEAYA Biosciences

    Uveal Melanoma

    phase 2 small molecule active

    1 trial

  18. NOV-002

    Cellectar Biosciences

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  19. NOV-002

    Cellectar Biosciences

    Leukemia

    phase 2 small molecule terminated

    1 trial

  20. NOV-205

    Cellectar Biosciences

    Hepatitis C

    phase 2 small molecule completed

    2 trials

  21. NPC-1C/NEO-102

    Chongqing Precision Biotech Co., Ltd

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  22. NPS 1776 (800 mg)

    Takeda

    Migraine Headache

    phase 2 small molecule completed

    1 trial

  23. NPSP795

    Takeda

    Autosomal Dominant Hypocalcemia (ADH)

    phase 2 small molecule completed

    1 trial

  24. NRX 194204

    IO Biotech

    Castration Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  25. NS-229 matching tablets with no active treatment, NS-229

    Lacuna Pharma Pty Ltd

    Eosinophilic granulomatosis with polyangiitis (EGPA)

    phase 2 small molecule active

    1 trial

  26. NS2

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 2 small molecule completed

    1 trial

  27. NS2 Ophthalmic Drops (0.5%)

    Aldeyra Therapeutics

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  28. NT219

    PURPLE BIOTECH LTD.

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  29. NT219

    PURPLE BIOTECH LTD.

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

  30. NTBC

    Ultragenyx UK Limited

    Tyrosinemia, Type I

    phase 2 small molecule completed

    1 trial

  31. NTX-001

    United Therapeutics Europe Ltd

    Peripheral Nerve Injuries

    phase 2 small molecule active

    1 trial

  32. NUBEQA 300 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Disc Medicine

    metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  33. NV-5138

    SUPERNUS PHARMACEUTICALS, INC.

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  34. NV-5138

    SUPERNUS PHARMACEUTICALS, INC.

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  35. NX-5948

    Nurix Therapeutics

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    2 trials

  36. NX-5948

    Nurix Therapeutics

    Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

    phase 2 small molecule active

    1 trial

  37. NX210c, GLUCOSE 5 % B.BRAUN, solution pour perfusion

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  38. NXC-201 CAR-T

    Immix Biopharma

    Light Chain (AL) Amyloidosis

    phase 2 mab active

    1 trial

  39. NY-ESO-1 Peptide vaccine

    Coherus Oncology

    Ovarian Cancer Stage IV

    phase 2 mab active

    1 trial

  40. NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 2 mab active

    1 trial

  41. NaCl 0,9%, Deferoxamine Noridem 500mg Κόνις για ενέσιμο διάλυμα ή διάλυμα για έγχυση

    Disc Medicine

    Subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  42. NaCl 0.9% solution

    GlaxoSmithKline

    Meningitis, Meningococcal

    phase 2 small molecule active

    1 trial

  43. NaCl 0.9%, GAMMA-OH 200 mg/ml, solution injectable (IV)

    Pari Pharma GmbH

    The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.

    phase 2 small molecule active

    1 trial

  44. NaCl solution

    GlaxoSmithKline

    Herpes Simplex

    phase 2 small molecule active

    1 trial

  45. Nab paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Metastatic Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  46. Nab-paclitaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  47. Nab-paclitaxel Combined With Cadonilimab (AK104)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  48. Nabilone

    BRIGHT MINDS BIOSCIENCES INC.

    Frontotemporal Dementia

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.